Diabetes and kidney cancer outcomes: a propensity score analysis

Endocrine

Volumn 55, Issue 2, 2017, Pages 470-477

  Nayan, Madhur ^a   Finelli, Antonio ^a   Jewett, Michael A S ^a   Juurlink, David N ^b   Austin, Peter C ^c,d,e   Kulkarni, Girish S ^a   Hamilton, Robert J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Canada   (Canada)

Author keywords

Diabetes mellitus; Kidney neoplasms; Nephrectomy; Propensity score; Survival

Indexed keywords

ANTIDIABETIC AGENT;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PROPENSITY SCORE; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TERTIARY CARE CENTER; AGED; CARCINOMA, RENAL CELL; COMPLICATION; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84994275834     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-016-1149-5     Document Type: Article

References (54)

1. International Agency for Research on Cancer, World Health Organization, GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012, Lyon, France (IARC, 2014)
2. A. Znaor, J. Lortet-Tieulent, M. Laversanne, A. Jemal, F. Bray, International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67(3), 519–530 (2014)
3. W.H. Chow, L.M. Dong, S.S. Devesa, Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7(5), 245–257 (2010). doi:10.1038/nrurol.2010.46
4. S.C. Larsson, A. Wolk, Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54(5), 1013–1018 (2011). doi:10.1007/s00125-011-2051-6
5. C. Bao, X. Yang, W. Xu, H. Luo, Z. Xu, C. Su, X. Qi, Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J. Diabetes Complications 27(4), 357–364 (2013). doi:10.1016/j.jdiacomp.2013.01.004
6. K.S. Peairs, B.B. Barone, C.F. Snyder, H.-C. Yeh, K.B. Stein, R.L. Derr, F.L. Brancati, A.C. Wolff, Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J. Clin. Oncol. 29(1), 40–46 (2011)
7. Y. Jiang, Q. Ben, H. Shen, W. Lu, Y. Zhang, J. Zhu, Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur. J. Epidemiol. 26(11), 863–876 (2011)
8. J.-Y. Lee, I. Jeon, J.M. Lee, J.-M. Yoon, S.M. Park, Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur. J. Cancer 49(10), 2411–2423 (2013)
9. J.C. Will, F. Vinicor, E.E. Calle, Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 10(3), 313–318 (1999)
10. A. Antonelli, N. Arrighi, S. Corti, T. Zanotelli, A. Cozzoli, S. Cosciani Cunico, C. Simeone, Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study. Urol. Oncol. 31(7), 1310–1315 (2013). doi:10.1016/j.urolonc.2011.12.013
11. H. Chung, S. Chen, M. Li, Diabetes and risk of death from cancer of the prostate, kidney, and urinary bladder. Urology 74(4 Suppl S), S36–S37 (2009). doi:10.1016/j.urology.2009.07.1106
12. S.S. Coughlin, J.D. Neaton, B. Randall, A. Sengupta, Predictors of mortality from kidney cancer in 332,547 men screened for the multiple risk factor intervention trial. Cancer 79(11), 2171–2177 (1997)
13. H. Fukushima, H. Masuda, M. Yokoyama, M. Tatokoro, S. Yoshida, J. Ishioka, Y. Matsuoka, N. Numao, F. Koga, K. Saito, Y. Fujii, K. Kihara, Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 43(7), 740–746 (2013). doi:10.1093/jjco/hyt070
14. Y.S. Ha, W.T. Kim, S.J. Yun, S.C. Lee, W.J. Kim, Y.H. Park, S.H. Kang, S.H. Hong, S.S. Byun, Y.J. Kim, Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann. Surg. Oncol. 20(11), 3662–3668 (2013). doi:10.1245/s10434-013-3147-7
15. T. Höfner, M. Zeier, G. Hatiboglu, C. Eisen, G. Schönberg, B. Hadaschik, D. Teber, S. Duensing, A. Trumpp, M. Hohenfellner, The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World J. Urol. 32(6), 1537–1542 (2014)
16. S.H. Jee, H. Ohrr, J.W. Sull, J.E. Yun, M. Ji, J.M. Samet, Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2), 194–202 (2005)
17. E.K. Lam, G.D. Batty, R.R. Huxley, A.L. Martiniuk, F. Barzi, T.H. Lam, C.M. Lawes, G.G. Giles, T. Welborn, H. Ueshima, A. Tamakoshi, J. Woo, H.C. Kim, X. Fang, S. Czernichow, M. Woodward, Asia Pacific Cohort Studies Collaboration: Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann. Oncol. 22(3), 730–738 (2011). doi:10.1093/annonc/mdq405
18. Y.J. Lee, J. Suh, M. Kim, M.S. Choo, S.B. Lee, H. Jeong, K. Park, W.S. Choi, C.W. Jeong, J.H. Ku, H.H. Kim, C. Kwak, Is diabetes mellitus associated with cancer specific and overall survival in localized clear cell renal cell carcinoma? J. Urol. 1, e654 (2014). doi:10.1016/j.juro.2014.02.1808
19. S. Steffens, C. Von Klot, H. Eggers, C. Seidel, G. Wegener, M. Schrader, M.A. Kuczyk, A.J. Schrader, The role of diabetes mellitus and obesity in localized and metastatic RCC. Eur. Urol. 11(1), e1018–e1018a (2012). Supplements
20. E. Suer, E. Ozturk, O. Gulpinar, A. Kayis, S. Baltaci, Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer. Korean J. Urol. 54(8), 499–503 (2013). doi:10.4111/kju.2013.54.8.499
21. A. Vavallo, S. Simone, G. Lucarelli, M. Rutigliano, V. Galleggiante, G. Grandaliano, L. Gesualdo, M. Campagna, M. Cariello, E. Ranieri, G. Pertosa, G. Lastilla, F.P. Selvaggi, P. Ditonno, M. Battaglia, Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine 93(27), (2014). doi:10.1097/MD.0000000000000183
22. M. Washio, M. Mori, K. Mikami, T. Miki, Y. Watanabe, M. Nakao, T. Kubo, K. Suzuki, K. Ozasa, K. Wakai, A. Tamakoshi, Cigarette smoking and other risk factors for kidney cancer death in a Japanese population: Japan Collaborative Cohort Study for evaluation of cancer risk (JACC study). Asian Pac. J. Cancer Prev. 14(11), 6523–6528 (2014)
23. X. Liu, J. Ji, K. Sundquist, J. Sundquist, K. Hemminki, The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 118(5), 1353–1361 (2012). doi:10.1002/cncr.26420
24. S.P. Psutka, S.B. Stewart, S.A. Boorjian, C.M. Lohse, M.K. Tollefson, J.C. Cheville, B.C. Leibovich, R.H. Thompson, Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J. Urol. (2014). doi:10.1016/j.juro.2014.06.014
25. K. Ranc, M.E. Jørgensen, S. Friis, B. Carstensen, Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia 57(5), 927–934 (2014)
26. P.T. Campbell, C.C. Newton, A.V. Patel, E.J. Jacobs, S.M. Gapstur, Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 35(9), 1835–1844 (2012). doi:10.2337/dc12-0002
27. E. Clarke, L. Marrett, N. Kreiger, Appendix 3 (c) Cancer registration in Ontario: a computer approach. Cancer Reg. 95, 246–257 (1991)
28. D.R. Brenner, M.C. Tammemagi, S.B. Bull, D. Pinnaduwaje, I.L. Andrulis, Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients. Chronic Dis. Can. 30(1), 16–19 (2009)
29. P.C. Austin, The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat. Med. 33(7), 1242–1258 (2014)
30. M. Nayan, A. Finelli, M. Jewett, D. Juurlink, P. Austin, G. Kulkarni, R. Hamilton, Statin use and kidney cancer survival outcomes: a propensity score analysis. Urol. Oncol. (2016). doi:10.1016/j.urolonc.2016.06.007
31. C.L. Atzema, K. Grewal, H. Lu, M.K. Kapral, G. Kulkarni, P.C. Austin, Outcomes among patients discharged from the emergency department with a diagnosis of peripheral vertigo. Ann. Neurol. (2015)
32. P.C. Austin, M.M. Mamdani, A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin use. Stat. Med. 25(12), 2084–2106 (2006)
33. P.C. Austin, E.A. Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661–3679 (2015)
34. M.A. Brookhart, R. Wyss, J.B. Layton, T. Stürmer, Propensity score methods for confounding control in nonexperimental research. Circulation 6(5), 604–611 (2013)
35. P.C. Austin, Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10(2), 150–161 (2011)
36. P.C. Austin, Assessing balance in measured baseline covariates when using many‐to‐one matching on the propensity‐score. Pharmacoepidemiol. Drug Saf. 17(12), 1218–1225 (2008)
37. P.C. Austin, Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083–3107 (2009)
38. S.R. Cole, M.A. Hernán, Adjusted survival curves with inverse probability weights. Comput. Methods Programs Biomed. 75(1), 45–49 (2004)
39. P.C. Austin, T. Schuster, The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study. Stat. Methods Med. Res. 25(5), 2214–2237 (2014)
40. D.Y. Lin, L.-J. Wei, Z. Ying, Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80(3), 557–572 (1993)
41. L. Chen, H. Li, L. Gu, X. Ma, X. Li, Y. Gao, Y. Zhang, D. Shen, Y. Fan, B. Wang, The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies. Medicine 94(26), e1055 (2015)
42. R.D. Riley, J.P. Higgins, J.J. Deeks, Interpretation of random effects meta-analyses. BMJ 342, d549 (2011). doi:10.1136/bmj.d549
43. R. Novosyadlyy, D.E. Lann, A. Vijayakumar, A. Rowzee, D.A. Lazzarino, Y. Fierz, J.M. Carboni, M.M. Gottardis, P.A. Pennisi, A.A. Molinolo, Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 70(2), 741–751 (2010)
44. A. Grothey, W. Voigt, C. Schöber, T. Müller, W. Dempke, H. Schmoll, The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J. Cancer Res. Clin. Oncol. 125(3–4), 166–173 (1999)
45. R. Baserga, F. Peruzzi, K. Reiss, The IGF-1 receptor in cancer biology. Int. J. Cancer 107(6), 873–877 (2003). doi:10.1002/ijc.11487
46. M. Nayan, B. Bhindi, L.Y. Julie, T. Hermanns, A. Mohammed, R. J. Hamilton, A. Finelli, M.A. Jewett, A.R. Zlotta, N.E. Fleshner, The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol. Oncol. 33(9), 386.e7–13 (2015). doi:10.1016/j.urolonc.2015.05.024
47. D. Margel, D.R. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkarni, P.C. Austin, N. Fleshner, Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 31(25), 3069–3075 (2013). doi:10.1200/JCO.2012.46.7043
48. N. Sadeghi, J.L. Abbruzzese, S.-C.J. Yeung, M. Hassan, D. Li, Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res. 18(10), 2905–2912 (2012)
49. M. Nayan, A. Finelli, M.A. Jewett, D.N. Juurlink, P.C. Austin, G.S. Kulkarni, R.J. Hamilton, Metformin use and kidney cancer outcomes in patients with diabetes: a propensity score analysis. Clin. Genitourin. Cancer (2016). doi:10.1016/j.clgc.2016.06.008
50. A.A. Hakimi, L. Chen, P.H. Kim, D. Sjoberg, L. Glickman, M.R. Walker, P. Russo, The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can. Urol. Assoc. J. 7(11–12), E687–E691 (2013). doi:10.5489/cuaj.1447
51. S.P. Psutka, S.A. Boorjian, C.M. Lohse, S.B. Stewart, M.K. Tollefson, J.C. Cheville, B.C. Leibovich, R.H. Thompson, The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol. Oncol. 33(2), 67.e15–23. doi:10.1016/j.urolonc.2014.07.008
52. M. Nayan, E.M. Macdonald, D.N. Juurlink, P.C. Austin, A. Finelli, G.S. Kulkarni, R.J. Hamilton, Medication use and survival in diabetic patients with kidney cancer: a population-based cohort study. Pharmacol. Res. 113, 468–474 (2016). doi:10.1016/j.phrs.2016.09.027
53. I. Frank, M.L. Blute, J.C. Cheville, C.M. Lohse, A.L. Weaver, H. Zincke, An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168(6), 2395–2400 (2002)
54. L.V. van de Poll-Franse, S. Houterman, M.L. Janssen-Heijnen, M.W. Dercksen, J.W. Coebergh, H.R. Haak, Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int. J. Cancer 120(9), 1986–1992 (2007). doi:10.1002/ijc.22532